Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? (Q38285316)

1 September 2017

1 reference

title

Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? (English)

1 reference

1 September 2017

Laura McCullagh

25

0 references

Irene Eriksson

Irene Eriksson

14

0 references

Brian Godman

Brian Godman

1

0 references

Lars L. Gustafsson

Lars L Gustafsson

40

0 references

Ilse Truter

33

Ilse Truter

1 reference

1 September 2017

2

Rickard E Malmström

1 reference

1 September 2017

10

Anna Bucsics

1 reference

1 September 2017

17

Jurij Fürst

1 reference

1 September 2017

21

Saira Jan

1 reference

1 September 2017

22

Roberta Joppi

1 reference

1 September 2017

23

Marija Kalaba

1 reference

1 September 2017

29

Gisbert Selke

1 reference

1 September 2017

30

Catherine Sermet

1 reference

1 September 2017

37

Janet Wale

1 reference

1 September 2017

3

Eduardo Diogene

1 reference

1 September 2017

5

Sisira Jayathissa

1 reference

1 September 2017

31

Susan Spillane

1 reference

1 September 2017

Vera Vlahović-Palčevski

34

Vera Vlahović-Palčevski

1 reference

1 September 2017

18

Kristina Garuoliene

1 reference

1 September 2017

Alexander E Finlayson

16

Alexander E Finlayson

1 reference

1 September 2017

Andy Gray

4

1 reference

1 September 2017

Angela Timoney

6

1 reference

1 September 2017

Francisco Acurcio

7

1 reference

1 September 2017

Ali Alkan

8

1 reference

1 September 2017

Anna Brzezinska

9

1 reference

1 September 2017

Stephen M Campbell

11

1 reference

1 September 2017

Jadwiga Czeczot

12

1 reference

1 September 2017

Winnie de Bruyn

13

1 reference

1 September 2017

Faridah Aryani Md Yusof

15

1 reference

1 September 2017

Augusto Guerra Júnior

19

1 reference

1 September 2017

Jolanta Gulbinovič

20

1 reference

1 September 2017

Einar Magnisson

24

1 reference

1 September 2017

Kaisa Miikkulainen

26

1 reference

1 September 2017

Gabriela Ofierska-Sujkowska

27

1 reference

1 September 2017

Hanne Bak Pedersen

28

1 reference

1 September 2017

Azuwana Supian

32

1 reference

1 September 2017

Low Ee Vien

35

1 reference

1 September 2017

Elif H Vural

36

1 reference

1 September 2017

Magdałene Władysiuk

38

1 reference

1 September 2017

Wenjie Zeng

39

1 reference

1 September 2017

language of work or name

English

0 references

publication date

1 January 2015

1 reference

Expert Review of Clinical Pharmacology

1 September 2017

1 reference

1 September 2017

8

1 reference

1 September 2017

77-94

1 reference

1 September 2017

1

1 reference

Identifying priority medicines policy issues for New Zealand: a general inductive study

1 September 2017

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Drug discovery: a historical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

New Expensive Treatments for Hepatitis C Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Cost-effectiveness assessment of orphan drugs: a scientific and political conundrum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Enhancing the rational use of new medicines across European health care systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Systematic review of factors affecting pharmaceutical expenditures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Treatment of hepatitis C: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Global estimates of the prevalence of diabetes for 2010 and 2030

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Sofosbuvir (Sovaldi) for the treatment of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Efficacy does not necessarily translate to cost effectiveness: a case study in the challenges associated with 21st-century cancer drug pricing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Personalizing health care: feasibility and future implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Pricing for orphan drugs: will the market bear what society cannot?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Introduction: Institutional corruption and the pharmaceutical policy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Pharmaceutical lobbying under postcommunism: universal or country-specific methods of securing state drug reimbursement in Poland?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Antiretroviral drug expenditure, pricing and judicial demand: an analysis of federal procurement data in Brazil from 2004-2011

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Information from pharmaceutical companies and the quality, quantity, and cost of physicians' prescribing: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Institutional corruption of pharmaceuticals and the myth of safe and effective drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Prevalence of financial conflicts of interest among panel members producing clinical practice guidelines in Canada and United States: cross sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Is there a cure for corporate crime in the drug industry?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Corruption of pharmaceutical markets: addressing the misalignment of financial incentives and public health

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Insight into recent reforms and initiatives in Austria: implications for key stakeholders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Cancer drugs in the United States: Justum Pretium--the just price

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Active pharmaceutical management strategies of health insurance systems to improve cost-effective use of medicines in low- and middle-income countries: a systematic review of current evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Interventions promoting the acceptance and uptake of generic medicines: a narrative review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Policies to promote use of generic medicines in low and middle income countries: a review of published literature, 2000-2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Different initiatives across Europe to enhance losartan utilization post generics: impact and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Analysis of the impact of removing mucolytics and expectorants from the list of reimbursable drugs on prescription rates: a time-series analysis for France 1998-2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Over 150 potentially low-value health care practices: an Australian study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Disinvestment for re-allocation: a process to identify priorities in healthcare.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Response to Michael Wonder's comments on the article 'Assessment of the therapeutic value of new medicines marketed in Australia'

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Macro trends in pharmaceutical innovation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Does placebo help establish equivalence in trials of new antidepressants?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Placebo? no thanks, it might be bad for me!

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

21 January 2018

2011 FDA drug approvals

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

How much will Herceptin really cost?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Incentives for new antibiotics: the Options Market for Antibiotics (OMA) model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

A New Reimbursement System for Innovative Pharmaceuticals Combining Value-Based and Free Market Pricing

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: a concise review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

The Diabetes Prevention Program (DPP): description of lifestyle intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Access to orphan drugs in Europe: current and future issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Shining a light in the black box of orphan drug pricing

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Access to orphan drugs despite poor quality of clinical evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Orphan drug development is not taking off.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme®) therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Personalized medicine. New cystic fibrosis drug offers hope, at a price.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Paying twice: questions over high cost of cystic fibrosis drug developed with charitable funding

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Cyclosporine versus tacrolimus in immunosuppressive maintenance regimens in renal transplants in Brazil: survival analysis from 2000 to 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Appropriateness of prescribing dabigatran etexilate and rivaroxaban in patients with nonvalvular atrial fibrillation: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Dabigatran: how the drug company withheld important analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Longterm Retention of Tumor Necrosis Factor- Inhibitor Therapy in a Large Italian Cohort of Patients with Rheumatoid Arthritis from the GISEA Registry: An Appraisal of Predictors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

The use of TNF-inhibitors in ankylosing spondylitis in Austria from 2007 to 2009 - a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

The ‘Wise List’- A Comprehensive Concept to Select, Communicate and Achieve Adherence to Recommendations of Essential Drugs in Ambulatory Care in Stockholm

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Interface management of pharmacotherapy. Joint hospital and primary care drug recommendations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

The Italian Horizon Scanning Project.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Analyzing 10 years of early awareness and alert activity in the United kingdom.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Scanning the horizon: development and implementation of an early awareness system for anticancer drugs in Austria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Information service on new and emerging health technologies: identification and prioritization processes for a European union-wide newsletter

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Forecasting drug utilization and expenditure in a metropolitan health region

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Hospitalized patients with atrial fibrillation compared to those included in recent trials on novel oral anticoagulants: a population-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Early scientific advice obtained simultaneously from regulators and payers: findings from a pilot study in Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Ahead of its time? Reflecting on New Zealand's Pharmac following its 20th anniversary.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Comment on "ahead of its time? Reflecting on New Zealand's Pharmac following its 20th anniversary" : clarification from PHARMAC: PHARMAC takes no particular distributive approach (utilitarian or otherwise)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

A review of Health Technology Assessment (HTA) recommendations for drug therapies issued between 2007 and 2009 and their impact on policymaking processes in Poland

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

A win-win solution?: A critical analysis of tiered pricing to improve access to medicines in developing countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

The role of discounts and loss leaders in medicine procurement in Austrian hospitals - a primary survey of official and actual medicine prices

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Mechanism of coordinated access to orphan drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

A prescription for improving drug formulary decision making

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

An analytical framework for assessing drug and therapeutics committee structure and work processes in tertiary Brazilian hospitals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Prescribing new drugs: qualitative study of influences on consultants and general practitioners

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Changes in the utilization of venlafaxine after the introduction of generics in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Policies to enhance the efficiency of prescribing in the Spanish Catalan region: impact and future direction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

Potential savings without compromising the quality of care

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.990380

10.1586/17512433.2015.990380

21 January 2018

Identifiers

DOI

1 reference

1 September 2017

1 reference